/ /

Lynda Charters
Lower treatment burden with aflibercept for CRVOs
Cystoid macular edema (CME) might become less problematic in patients with non-ischemic central retinal vein occlusions (CRVOs).
Toward emmetropia: More advances, more improvements
Advances in treatments for keratoconus and presbyopia in 2016 continued to move patients toward emmetropia.
Long-term aflibercept effective for nAMD after other anti-VEGF therapies failed
Aflibercept (Eylea, Regeneron Pharmaceuticals) intravitreal injection, administered according to an as-needed regimen, improved the anatomic outcomes in many eyes refractory to monthly bevacizumab or ranibizumab injections that had persistent or recurrent fluid. However, half of the patients might require aflibercept injections every 4 weeks in order to achieve a completely dry retina.
Topical treatment for neovascular AMD within sight
A novel vascular endothelial growth factor receptor 2 (VEGF-R2) topical eye drop, PAN-90806 (PanOptica, Inc.), may revolutionize the treatment of neovascular age-related macular degeneration by making intravitreal injections of anti-VEGF drugs a thing of the past for certain patients and eliminating the risk associated with the intravitreal injections.
Topical ENaC blocker serves as novel approach to tear film
A novel potent epithelial sodium channel blocker seems to be a safe and well-tolerated therapy in patients with symptoms of mild-to-moderate dry eye disease compared with placebo.
No-stitch blepharoplasty: Revisiting use of tissue adhesive
Tissue adhesive has a place in blepharoplasty but the caveat is that patient selection is extremely important.
Epi-on CXL: Safe, effective option for treating thin corneas
Patients with thin corneas as the result of keratoconus, ectasia following LASIK, or pellucid marginal degeneration can safely undergo epithelial-on collagen crosslinking with pulsed UV light and achieve visual benefits from the procedure.
Lower treatment burden with earlier administration of anti-VEGF therapy for DME
Earlier treatment of patients with DME who have had visual acuity loss results in the need for fewer intravitreal injections of ranibizumab over the long term.
Sustained-release intravitreal implant is viable alternative to anti-VEGFs for DME patients
A real-world safety study of fluocinolone acetonide implant (Iluvien, Alimera Sciences) in patients with chronic DME (328 eyes from 292 patients) showed that 81.6% of patients did not require initiation of IOP-lowering therapy during the study and 60% of patients included in this registry study gained vision after injection of Iluvien that was sustained over the study period.
Anti-VEGF induces regression of diabetic retinopathy in high-risk populace
When followed over time, about 75% of patients in the RIDE/RISE trials who had the highest risk of progression to proliferative diabetic retinopathy benefited from ranibizumab with “robust” regression of diabetic retinopathy severity levels.


View Results